多模式联合治疗晚期巨大肝癌1例。

IF 2.5 Q2 GASTROENTEROLOGY & HEPATOLOGY
Translational gastroenterology and hepatology Pub Date : 2025-01-17 eCollection Date: 2025-01-01 DOI:10.21037/tgh-24-91
Shan Li, Zhen-Feng Zhou, Hao-Jian Long, Jia-Xin Yin, Hui-Zhong Wang, Jian-Fu Zhao
{"title":"多模式联合治疗晚期巨大肝癌1例。","authors":"Shan Li, Zhen-Feng Zhou, Hao-Jian Long, Jia-Xin Yin, Hui-Zhong Wang, Jian-Fu Zhao","doi":"10.21037/tgh-24-91","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a highly malignant tumor of the digestive system with a poor prognosis. Huge HCC, a subtype characterized by tumors measuring at least 10 cm in diameter, often presents with macrovascular invasion, satellite nodules, metastases, and other aggressive characteristics, posing significant challenges for treatment. The era of combined targeted therapy and immunotherapy has brought new hope to patients with advanced HCC. The development of innovative combination medication regimens for HCC is a current area of intense clinical research interest. We are trying to explore new combination therapies based on target-immunity combination therapy in the hope of better-benefiting patients with advanced huge HCC.</p><p><strong>Case description: </strong>We present a patient with Barcelona Clinical Liver Cancer Stage C huge HCC who was treated with combined targeted therapy and immunotherapy as the primary therapeutic regimen, supplemented with tegafur long-term metronomic chemotherapy, as well as specialized adjuvant therapy such as thymosin, bisphosphonates, antiviral medication, and vitamin C supplementation. The tumor size was significantly reduced and microwave ablation was performed, after which, the patient was kept on the combination regimen, resulting in a partial response (PR), and maintaining PR without disease progression for 32 months.</p><p><strong>Conclusions: </strong>The combination regimen may enhance advanced huge HCC treatment and provide a new multimodal drug strategy for HCC.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"17"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811550/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: a case report.\",\"authors\":\"Shan Li, Zhen-Feng Zhou, Hao-Jian Long, Jia-Xin Yin, Hui-Zhong Wang, Jian-Fu Zhao\",\"doi\":\"10.21037/tgh-24-91\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a highly malignant tumor of the digestive system with a poor prognosis. Huge HCC, a subtype characterized by tumors measuring at least 10 cm in diameter, often presents with macrovascular invasion, satellite nodules, metastases, and other aggressive characteristics, posing significant challenges for treatment. The era of combined targeted therapy and immunotherapy has brought new hope to patients with advanced HCC. The development of innovative combination medication regimens for HCC is a current area of intense clinical research interest. We are trying to explore new combination therapies based on target-immunity combination therapy in the hope of better-benefiting patients with advanced huge HCC.</p><p><strong>Case description: </strong>We present a patient with Barcelona Clinical Liver Cancer Stage C huge HCC who was treated with combined targeted therapy and immunotherapy as the primary therapeutic regimen, supplemented with tegafur long-term metronomic chemotherapy, as well as specialized adjuvant therapy such as thymosin, bisphosphonates, antiviral medication, and vitamin C supplementation. The tumor size was significantly reduced and microwave ablation was performed, after which, the patient was kept on the combination regimen, resulting in a partial response (PR), and maintaining PR without disease progression for 32 months.</p><p><strong>Conclusions: </strong>The combination regimen may enhance advanced huge HCC treatment and provide a new multimodal drug strategy for HCC.</p>\",\"PeriodicalId\":94362,\"journal\":{\"name\":\"Translational gastroenterology and hepatology\",\"volume\":\"10 \",\"pages\":\"17\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811550/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational gastroenterology and hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/tgh-24-91\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational gastroenterology and hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/tgh-24-91","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:肝细胞癌(HCC)是一种高度恶性的消化系统肿瘤,预后不良。巨大HCC是一种以直径至少10cm的肿瘤为特征的亚型,通常表现为大血管侵袭、卫星结节、转移和其他侵袭性特征,给治疗带来了重大挑战。靶向治疗与免疫治疗联合的时代给晚期HCC患者带来了新的希望。HCC的创新联合用药方案的开发是当前临床研究的热点领域。我们正在尝试在靶向免疫联合治疗的基础上探索新的联合治疗方法,希望能更好地造福晚期巨大肝癌患者。病例描述:我们报告了一位巴塞罗那临床肝癌C期巨大HCC患者,以联合靶向治疗和免疫治疗为主要治疗方案,辅以替加氟长期节律化疗,以及胸腺肽、双膦酸盐、抗病毒药物和维生素C补充等专门辅助治疗。肿瘤大小明显减小,行微波消融治疗后,患者继续联合用药,部分缓解(PR), PR维持32个月无疾病进展。结论:联合用药方案可加强晚期巨量肝癌的治疗,为肝癌治疗提供一种新的多模式药物治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: a case report.

Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: a case report.

Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: a case report.

Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: a case report.

Background: Hepatocellular carcinoma (HCC) is a highly malignant tumor of the digestive system with a poor prognosis. Huge HCC, a subtype characterized by tumors measuring at least 10 cm in diameter, often presents with macrovascular invasion, satellite nodules, metastases, and other aggressive characteristics, posing significant challenges for treatment. The era of combined targeted therapy and immunotherapy has brought new hope to patients with advanced HCC. The development of innovative combination medication regimens for HCC is a current area of intense clinical research interest. We are trying to explore new combination therapies based on target-immunity combination therapy in the hope of better-benefiting patients with advanced huge HCC.

Case description: We present a patient with Barcelona Clinical Liver Cancer Stage C huge HCC who was treated with combined targeted therapy and immunotherapy as the primary therapeutic regimen, supplemented with tegafur long-term metronomic chemotherapy, as well as specialized adjuvant therapy such as thymosin, bisphosphonates, antiviral medication, and vitamin C supplementation. The tumor size was significantly reduced and microwave ablation was performed, after which, the patient was kept on the combination regimen, resulting in a partial response (PR), and maintaining PR without disease progression for 32 months.

Conclusions: The combination regimen may enhance advanced huge HCC treatment and provide a new multimodal drug strategy for HCC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信